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1552-5260/ 2017 Thing Test (FCSRT) as a sensitive detector of the amnesic syndrome of the hippocampal type in typical
Alzheimer’s disease (AD). But does it differentiate AD from other neurodegenerative diseases?
Methods: We assessed the FCSRT and cerebrospinal fluid (CSF) AD biomarkers in 992 cases. Ex-
perts, blinded to biomarker data, attributed in 650 cases a diagnosis of typical AD, frontotemporal
dementia, posterior cortical atrophy, Lewy body disease, progressive supranuclear palsy, corticobasal
syndrome, primary progressive aphasias, “subjective cognitive decline,” or depression.
Results: The FCSRT distinguished typical AD from all other conditions with a sensitivity of 100%
and a specificity of 75%. Non-AD neurodegenerative diseases with positive AD CSF biomarkers
(“atypical AD”) did not have lower FCSRT scores than those with negative biomarkers.
Discussion: The FCSRT is a reliable tool for diagnosing typical AD among various neurodegener-
ative diseases. At an individual level, however, its specificity is not absolute. Our findings also widen
the spectrum of atypical AD to multiple neurodegenerative conditions.
 2017 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.Keywords: Alzheimer’s disease; Neurodegenerative diseases; Assessment of memory disorders; Dementia1. Introduction
In clinical and pharmacological trials targeting Alz-
heimer’s disease (AD), the most prevalent neurodegenera-
tive disease in the world [1], the use of highly specificTeichmann, Stephane Epelbaum, Dalila Samri, Fou-
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e Alzheimer’s Association. Published by Elsevier Inc. All rneuropsychological tests is indispensable for identifying
the typical AD phenotype to avoid erroneous patient inclu-
sions. Efficient neuropsychological tests would also
decrease negative results of invasive second-line examina-
tions such as lumbar puncture for cerebrospinal fluid
(CSF) biomarker analyses, which might have a significant
impact on the costs and the outcome of such trials. In this
vein, the Free and Cued Selective Reminding Test (FCSRT)
has been recommended by the International Working Group
(IWG) as a reliable tool for the assessment of episodic mem-
ory failure that constitutes the core feature of typical
amnesic AD [2,3].ights reserved.
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30 years [4–10]. It evaluates the ability to learn a list of 16
written words that are presented with a semantic cue to
control for memory encoding. Memory recall is then
assessed by asking to retrieve the words first
spontaneously (“free recall”) and then with the help of a
semantic cue for those items that were not retrieved (“total
recall” 5 “free recall” 1 “cued recall”) [6]. In contrast
with most of the other memory tests the main advantages
of the FCSRT are (1) that the encoding of the items is
controlled by cuing to exclude “simple” attention disorders
and (2) that semantic cuing facilitates the retrieval of stored
information thus distinguishing between simple retrieval dif-
ficulties (facilitated by cuing), encountered, for example, in
frontal dysfunction, and genuine storage deficits character-
izing typical AD (not facilitated by cuing). Furthermore, in-
trusions, that is, erroneously produced items during the cued
recall, suggest amnesic distortions reflecting impaired
episodic memory storage. Hence, the FCSRT enables the
identification of memory storage failure defining the
amnesic syndrome of the hippocampal type [11], primarily
characterized by insensitivity to cueing and by low total
recall. Given that the amnesic syndrome of the hippocampal
type has been shown to be strongly related to typical AD
[10], even at a prodromal stage of the disease [9], the IWG
proposed in 2007 to implement the FCSRT within the core
diagnostic criteria of typical AD [2].
However, the aforementioned studies assessing the
discriminative diagnosis value of the FCSRT suffer from
several limitations. First, they were conducted in research
settings exploring relatively small patient cohorts or focus-
sing mainly on AD and, besides some exceptions, without
including other identified neurodegenerative diseases. Sec-
ond, they did not use the gold-standard core feasible CSF
biomarkers to identify the underlying pathophysiology of
AD that would have decreased the risk of false diagnoses.
In the present study, we aimed at evaluating the reliability
of the FCSRT to detect typical AD in a large-scale monocen-
tric memory-clinic cohort of patients with various neurode-
generative diseases who underwent standardized CSF
biomarker assessments and who were clinically diagnosed
having AD or eight other age-related clinically relevant
neurodegenerative diseases, subjective cognitive decline
(SCD) [12], or depression. CSF biomarkers were used as
biological surrogate markers according to the current
research criteria of Dubois et al. [3], allowing for the
in vivo characterization of underlying Alzheimer’s pathol-
ogy. No definitive neuropathological data were available at
the time of the present study.2. Methods
2.1. Patient cohort and data banking
Patients were recruited in our tertiary memory center
(Institute for Memory and AD, Pitie-Salpêtriere UniversityHospital, Paris). This institute includes the national referral
centers for “Young Onset AD” and for “Rare Dementias.”
French guidelines for the evaluation of such patients recom-
mend a standardized neuropsychological evaluation, brain
imaging, and the analysis of the AD CSF biomarker profile
[13]. Our large-scale cohort of patients with typical AD and
other neurocognitive diseases (“ClinAD”) consists of a total
of 992 patients followed at our center from 2005 to 2014. All
had extensive neurological and neuropsychological evalua-
tions and underwent lumbar puncture for the analysis of
CSFAD biomarkers. They also had neuroimaging with mag-
netic resonance imaging (MRI) (n 5 295), and/or with
single-photon emission–computed tomography and/or
18F-2-fluoro-2-desoxy-D-glucose positron emission tomog-
raphy (FDG-PET) (n5 210). Four experienced neurologists
(MT, SE, ML, and AM) reviewed the patient files, blinded to
the biomarker results, and checked and validated consecu-
tively the diagnosis for each participant. A neuropsycholo-
gist (DS) collected data of the Mini-Mental State
Examination (MMSE) [14], the Frontal Assessment Battery
(FAB) [15], and the FCSRT [6,16]. The amnesic syndrome
of the hippocampal type, operationalized according to
Sarazin et al. [9], by a free recall less than 17 of 48 or a total
recall less than 40 of 48, was searched in each participant us-
ing a computerized patient file (e-CRF) filled in prospec-
tively and allowing for data extraction (http://en.evolucare.
com/patient-file-software.html). These FCSRT cut-off
values, indicating memory storage deficits, have been
derived from the identification of mild cognitive impairment
(MCI) subjects who declined to dementia stages of AD as
opposed to MCI subjects who remained stable over time
[9]. CSF biomarker values were entered into a second data-
base in our biochemistry department. The two databases
were then merged, anonymized, and monitored. All clinical
and biological data were generated during a routine clinical
work-up and were retrospectively extracted for the purpose
of this study. Therefore, according to French legislation,
explicit consent was waived. However, regulations concern-
ing electronic filing were followed, and patients and their
relatives were informed that anonymized data could be
used in research investigations and particularly for the pre-
sent study. Moreover, the local ethical committee approved
this study in participants with SCD who gave their signed
informed consent.2.2. Diagnosis procedure
The diagnosis for typical AD was based on international
consensus research criteria (prodromal and dementia stages)
[3] but taking into account exclusively the clinical pheno-
type independently from, and blinded to, CSF biomarkers.
Typical AD patients had an amnesic syndrome of the hippo-
campal type, associated or not with nonpredominant symp-
toms of aphasia, apraxia, agnosia, or executive disorders.
The identification of the amnesic syndrome of the hippo-
campal type was based on the application of the FCSRT
M. Teichmann et al. / Alzheimer’s & Dementia - (2017) 1-11 3that contained the following test stages: (1) learning a list of
16 written words presented with a semantic cue to control for
memory encoding; (2) assessing memory recall by asking to
retrieve the 16 words first spontaneously (free recall) and
then with the help of a semantic cue for those items that
were not spontaneously retrieved (total recall 5 free
recall1 cued recall); (3) repeating the procedure three times
to provide a free recall and a total recall score of 48; (4)
calculating the sensitivity to cueing by the formula ([“sum
of the 3 total recalls” 2 “sum of the 3 free recalls”]/[48 2
“sum of the 3 free recalls”]); (5) reapplying the same test
procedure 30 minutes later to evaluate the free delayed recall
and the total delayed recall; and (6) exploring the ability to
recognize the tested items (seen versus not seen).
International diagnostic criteria were also applied to iden-
tify the clinical phenotype of eight other neurodegenerative
diseases of the study cohort: frontotemporal dementia of the
behavioral type (bv-FTD) [17], primary progressive aphasia
(PPA)of the logopenic (lv-PPA), semantic (sv-PPA),or nonflu-
ent/agrammatic (nfv-PPA) type [18], corticobasal syndrome
(CBS) [19], progressive supranuclear palsy (PSP) [20], poste-
rior cortical atrophy (PCA) [21], and Lewy body disease
(LBD) [22]. International diagnostic criteriawere used to iden-
tify SCD [12] and depression [23]. More specifically,
regarding depression, we applied the Montgomery-Asberg
Depression Rating Scale (MADRS) [24] to quantify and to
screen for major depressive syndromes (MADRS  20), ac-
cording to the Diagnostic and Statistical Manual of Mental
Disorders (Fifth Edition) [23]. Major depression was also
confirmed by an extensive psychological examination. In the
“depression group” of the study there were no patients with
degenerative diseases or lesion-related depression as reflectedFig. 1. Diagnostic distributionof typicalAlzheimer’s disease (AD), theeight other neby normal MRI, FDG-PET, and/or CSF biomarkers and the
absence of cognitive decline during follow-up. Furthermore,
in the groups of neurodegenerative diseases, the rate of major
depressionwas low (,10%according to theMADRS), and the
proportion of such depressed patients was equivalent in these
groups that allowed for avoiding intergroup biases concerning
the interpretation of abnormal FCSRT scores.
The FCSRT, MMSE, and FAB were applied to all partic-
ipants. Patients with significant vascular brain lesions or
mixed diseases were excluded from further analyses to avoid
mixtures of vascular and degenerative processes. More spe-
cifically, we used the MRI staging of Fazekas et al. [25] to
exclude patients with significant lesions of vascular origin
(Fazekas score . 2), which might interfere with cognitive/
memory functioning and, therefore, generate biases
regarding FCSRT results. Only slight lesions of leucoaraio-
sis were accepted for inclusion in the study. Furthermore,
given that MRI white matter hyperintensities in neurodegen-
erative diseases are not necessarily vascular lesions, but
might reflect the degenerative process itself, we did not
exclude patients with hyperintensities that were not obvi-
ously of vascular origin such as juxtacortical/periventricular
patterns next to atrophied cortical regions [26].
A subsample of 30 patients was diagnosed by each of the
four expert neurologists to calculate interrater reliability co-
efficients.2.3. CSF biomarkers
CSF analyses were performed at the clinical biochemistry
department of the Pitie-Salpêtriere University Hospital,
including the quantification of total tau protein (t-tau), tauurodegenerative diseases, subjective cognitive decline (SCD), and depression.
Table 1




Typical AD (n 5 216)
FTD (n 5 69) CBS (n 5 59) PSP (n 5 16)
AD dementia
(n 5 200) Prodromal AD (n 5 16)
Sex, female 340 (52.3%) 118 (59%) 7 (43.7%) 32 (46.4%) 33 (55.9%) 4 (25%)*
Years of education 11.1 (4.5) 10.5 (0.3) 12 (1.2) 11.4 (0.5) 10.5 (0.6) 11.9 (1.2)
Age at symptom onset 64.1 (9.3) 64.5 (0.6) 69.7 (2.3)* 62.8 (1.1) 67 (1.2) 67.1 (2.2)
Age at first cognitive evaluation 67.6 (9) 68 (0.7) 72.5 (2.3) 67.1 (1.1) 69.7 (1.2) 70.4 (2.4)
Age at CSF biomarker evaluation 67.9 (8.9) 68.1 (0.6) 72.8 (2.3) 67 (1) 70.2 (1.1) 71.1 (2.2)
Neuropsychology
MMSE (/30) 21.4 (6.5) 19.1 (0.5) 26.1 (1.6)*** 21.6 (0.8) 21.2 (0.9) 22.9 (1.8)
FAB (/18) 12 (4.2) 11.6 (0.3) 15.4 (1.1)*** 10.8 (0.6)* 10.1 (0.6)** 10.2 (1.2)
FCSRT free recall (/48) 17.6 (9.1) 10.2 (0.5) 10.9 (1.5) 18 (1.1)*** 19.7 (1.2)*** 17.2 (2)**
FCSRT total recall (/48) 36.5 (10.3) 27.4 (1.1) 28.9 (2.8) 38.9 (1.5)*** 40.9 (1.9)*** 38.1 (3.6)*
FCSRT react to cueing 67.4 % (24.1) 46.4 (2.2) 53.4 (6.1) 73.4 (3.4)*** 80.4 (4.2)*** 72.8 (7.8)**
FCSRT free delayed re (/16) 6.1 (4.4) 2.7 (0.3) 1.9 (0.8) 6.4 (0.5)*** 6.8 (0.6)*** 6.8 (1)***
FCSRT total delayed re (/16) 12.2 (4.1) 8.6 (0.5) 8.1 (1.3) 12.8 (0.6)*** 13.8 (0.8)*** 12.9 (1.5)*
FCSRT recognitions 14.7 (2.2) 13.6 (0.3) 14.6 (0.8) 14.9 (0.4)* 14.8 (0.4) 15.1 (0.8)
FCSRT false recognitions 1.2 (2.9) 2.6 (0.4) 0.9 (1.2) 1.6 (0.8) 0.2 (0.6)** 0.8 (1.2)
FCSRT intrusions 3.8 (5.3) 8.4 (0.7) 6.1 (2) 3 (1)*** 1.7 (1.2)*** 1.5 (2.3)*
ASHT 211 (32.5 %) 200 (100%) 16 (100%) 22 (31.9%)*** 13 (22.0%)*** 6 (37.5%)
CSF biomarkers
CSF Ab 537.4 (276.4) 372.8 (8) 416.1 (28.6) 652.9 (21.4)*** 514.4 (21)*** 646.6 (35.4)***
CSF tau 480.9 (314) 711.2 (21.5) 708 (76.1) 325.2 (35)*** 376.8 (38.4)*** 280.9 (76.6)***
CSF p-tau 66.9 (38.1) 91.7 (2.7) 99.7 (9.6) 42.6 (4.2)*** 56.4 (4.9)*** 37.8 (9.3)***
CSF p-tau/Ab 0.17 (0.15) 0.27 (0.01) 0.26 (0.04) 0.08 (0.02)*** 0.14 (0.02)*** 0.06 (0.03)***
CSF AD profile 282 (43.4) 200 (100%) 16 (100%) 10 (14.5)*** 27 (45.8%) 0 (0%)***
Abbreviations: Ab, amyloid b; AD, Alzheimer’s disease; ASHT, amnesic syndrome of the hippocampal type; CBS, corticobasal syndrome; CSF, cerebro-
spinal fluid; FAB, Frontal Assessment Battery; FCSRT, Free and Cued Selective Reminding Test; FTD, frontotemporal dementia; free delayed re, free delayed
recall; LBD, Lewy body disease; lv-PPA, logopenic primary progressive aphasia; MMSE, Mini-Mental State Examination; nfv-PPA, nonfluent/agrammatic
primary progressive aphasia; PCA, posterior cortical atrophy; PSP, progressive supranuclear palsy; p-tau, phosphorylated tau; react to cueing, reactivity to
cueing; SCD, subjective cognitive decline; sv-PPA, semantic primary progressive aphasia; total delayed re, total delayed recall.
NOTE. In brackets: standard deviations or %. The two “Typical AD” columns 5 comparison between AD dementia and prodromal AD. All subsequent
columns 5 comparison between AD and the other neurodegenerative conditions, depression, and SCD. *P , .05, **P , .01, ***P , .001.
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yloid-b 1–42 (Ab1–42) peptide. CSF samples were centri-
fuged for 10 min at 3500 rpm at 4C to remove cells,
aliquoted to 0.4 mL samples in polypropylene tubes, and
then stored at 280C until analysis. Biomarker concentra-
tions of t-tau, p-tau181, and Ab1–42 were analyzed in dupli-
cate using the double antibody sandwich ELISA method
(Fujirebio). We also calculated derived ratios from single
biomarkers including t-tau/Ab1–42 and p-tau181/Ab1–42 ra-
tios. The ratio cut-off indicative of AD was set at p-tau181/
Ab1–42.0.11 based on studies with postmortem verification
of AD diagnosis [27,28] and on a large longitudinal
monocentric cohort [29]. This stringent approach was used
to provide robust cut-offs validated by neuropathological ex-
aminations, even if some authors consider that individual
biomarker abnormalities of, for example, Ab1–42 might be
sufficient to identify AD [30].2.4. Statistical analyses
T-tests were performed between prodromal and dementia
stage AD and then between all AD patients and the othergroups. Statistical significance was considered when P was
inferior to .05. We then dichotomized the non-AD groups
based on the CSF profile indicative, or not, of underlying
Alzheimer’s pathology to identify atypical variants of AD
in all the eight neurodegenerative conditions and to explore
whether underlying Alzheimer’s pathology as such might
affect memory scores of the FCSRT. Furthermore, we con-
ducted correlation analyses using linear regressions to iden-
tify whether CSF biomarker values (p-tau181/Ab1–42 ratio)
have an relationship with FCSRT scores in the AD group,
in the entire group of the eight other neurodegenerative con-
ditions, and in the whole group of degenerative diseases (AD
plus the eight other neurodegenerative conditions). All sta-
tistical analyses were performed using the jmp software
(SAS, 2007).3. Results
3.1. Patient cohort (ClinAD)
Among the 992 cases, 342 were excluded from the ana-
lyses because of significant vascular disease on MRI or
because of mixed disease patterns. The remaining 650
LBD (n 5 44) PCA (n 5 22) Sv-PPA (n 5 41) Lv-PPA (n 5 52) Nfv-PPA (n 5 11) Depression (n 5 71) SCD (n 5 49)
11 (25%)* 13 (59.1%) 19 (46.3%) 22 (42.3%) 9 (81.8%) 46 (64.8%) 26 (53.1%)
11.7 (0.7) 11.3 (1) 11.9 (0.7) 11.6 (0.6) 9.8 (1.3) 10.5 (0.5) 12.6 (0.7)**
67.7 (1.3) 59 (1.9)** 62.6 (1.4) 64.7 (1.2) 66.4 (2.7) 58.4 (1.1)*** 66.4 (1.5)
70.7 (1.3) 62.3 (1.9)** 66.4 (1.5) 68.2 (1.3) 70.6 (2.7) 62.1 (1.1)*** 69.6 (1.6)
71.3 (1.3) 62.8 (1.9)** 66.4 (1.4) 68.5 (1.2) 71.2 (2.7) 63.2 (1.1)*** 69.6 (1.5)
20.9 (1) 18.2 (1.3) 21 (1) 17.7 (1)* 22.6 (1.9) 25.6 (0.7)*** 28.4 (0.9)***
11.6 (0.7) 10.2 (1) 12 (0.7) 10.2 (0.6)** 11.9 (1.2) 14.2 (0.5)*** 16.4 (0.6)***
15.2 (1.2)** 18.6 (1.7)*** 15.3 (1.8)* 20.4 (1.8)*** 22.9 (2.4)*** 21.5 (0.9)*** 29.6 (1.1)***
36.2 (2.1)** 41.3 (3)*** 32.6 (3.1)* 43.4 (3)*** 43 (4)** 40 (1.3)*** 45.8 (1.3)***
66.4 (4.5)** 78.3 (6.5)*** 56 % (6.8) 85.6 (6.5)*** 85.9 (8.5)*** 72.6 (2.8)*** 88.7 (3)***
4.1 (0.6) 7.4 (0.9)*** 6.4 (0.9)*** 9 (0.8)*** 8.9 (1.1)*** 7.6 (0.4)*** 10.8 (0.6)***
12.6 (0.9)*** 15 (1.3)*** 12 (1.3)*** 14.7 (1.2)*** 14.9 (1.6)*** 13.4 (0.5)*** 15.6 (0.5)***
14.4 (0.5) 15.8 (0.7)* 15.6 (0.7)* 15.7 (0.7)* 15.4 (0.9) 14.8 (0.3)* 16 (0.3)***
0.6 (0.7)* 0.3 (1) 2.2 (1) 0.08 (1)* 0.3 (1.3) 0.5 (0.4)** 0.05 (0.4)***
2.3 (1.3)*** 2.7 (1.9)* 2.6 (2)*** 0.8 (1.9)*** 1 (2.6)* 2.3 (0.8)*** 0.9 (0.7)***
18 (40.9%) 5 (22.7)** 9 (22%) 3 (5.8%)*** 3 (27.3%)** 26 (36.6%)*** 0 (0%)***
461 (23.1)** 393.4 (30.1) 605.4 (26)*** 437.4 (21.9)* 659.6 (47.6)*** 817.7 (22.2)*** 827.1 (31.7)***
282 (44.1)*** 516.4 (65.9)* 396.2 (46.4)*** 650.4 (44.5) 370.7 (92.5)*** 255.7 (33.5)*** 281.8 (35.9)***
46.3 (5.5)*** 71.2 (8.1)* 59 (6.1)*** 83.7 (5.4) 57.3 (11.5)** 46.1 (4.1)*** 48.5 (4.6)***
0.12 (0.02)*** 0.2 (0.03) 0.14 (0.02)*** 0.24 (0.02) 0.12 (0.04)** 0.06 (0.01)*** 0.07 (0.02)***
22 (50%)*** 18 (81.8%) 15 (36.6%) 41 (78.8%)** 5 (45.4)*** 7 (9.9%)*** 7 (14.3%)***
Table 1
Continued.
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typical AD (n 5 216, dementia stage n 5 200, prodromal
stage n 5 16), bv-FTD (n 5 69), PPA (n 5 104, lv-PPA
n 5 52, sv-PPA n 5 41, nfv-PPA n 5 11), CBS (n 5 59),
PSP (n 5 16), PCA (n 5 22), LBD (n 5 44), SCD
(n 5 49), and depression (n 5 71). In the subsample of 30
patients diagnosed by each of the 4 expert neurologists,
the interrater reliability assessment coefficients were .0.9.
It should be noted that the sample size of the eight non-
AD conditions is smaller than the size of the typical AD
group reflecting lower prevalence of these eight neurodegen-
erative conditions. The sample sizes are, however, not negli-
gible thus allowing for statistically informative results. The
distribution of the different diagnostic groups is represented
in Fig. 1.3.2. CSF biomarkers
Of the 650 subjects, 368 (56.6%) exhibited a CSF profile
indicative of underlying Alzheimer’s pathology. Among
these, 200 of 200 were classified in the AD dementia group
(100%), 16 of 16 in the prodromal AD group (100%), 138 of314 (43.9%) in the other neurodegenerative diseases, and 14
of 120 in the depression and SCD group (11.7%). Among the
other neurodegenerative diseases, the PCA and the lv-PPA
groups contained 81.8% and 78.8% cases with positive
AD biomarker profiles, respectively. Positive CSF bio-
markers were also found in LBD (50%), CBS (45.8%),
nfv-PPA (45.4%), sv-PPA (36.6%), and bv-FTD (14.5%).
An AD biomarker profile had, therefore, and by definition,
a sensitivity of 100% but a rather low specificity (56.1%)
for identifying typical AD of the amnesic form among all
the other neurodegenerative diseases. Patients with positive
or negative CSF biomarkers did not differ in terms of age,
sex, or educational level. Demographic and biomarker data
are summarized in Table 1.3.3. Free and Cued Selective Reminding Test
In the AD group (dementia and prodromal stage), FCSRT
scores were abnormal as compared with normative data [9],
whereas the MMSE and the FAB were only impaired at the
dementia stage. Abnormal FCSRT scores, that is, free recall
less than 17 of 48 or total recall less than 40 of 48, had by
Fig. 2. Neuropsychological scores per diagnosis group (means, standard deviations) and each pair Student’s t-test representation. Note the clear separation of
Alzheimer’s disease (AD) from all other diagnosis groups for the Free and Cued Selective Reminding Test (FCSRT) total delayed recall and the number of
intrusions.
M. Teichmann et al. / Alzheimer’s & Dementia - (2017) 1-116definition a sensitivity of 100%, but a lower specificity of
74.8%, to identify typical AD, at dementia and prodromal
stages, among all other degenerative diseases. MMSE and
FAB scores were similar in AD dementia and in all the other
neurodegenerative diseases. The delayed total recall and thenumber of intrusions during the total recall of the FCSRT
were significantly more impaired in typical AD than in the
other groups, reflecting poorer performance in long-term
verbal memory and the presence of amnesic distortions spe-
cific of typical AD (see Table 1 and Fig. 2). The best
Table 2











































Age at first cognitive
evaluation




69.4 (2) 66.4 (1) 67.7 (2.3) 65.6 (1.8) 72 (4.6) 70.5 (4.2) 62.4 (1.6) 64.2 (3.5) 70.9 (1.4) 69.7 (1.3) 67.4 (1.2) 65.3 (3.1) 70.8 (1.5) 71.8 (1.5) 60.2 (1.2) 67.1 (3.3)
Neuro psychology
MMSE 16.1 (1.1) 23 (2)* 22.3 (1.3) 18.3 (1.9) 24.6 (3) 21 (2.7) 17 (1.4) 24 (3)* 21.4 (1.3) 21 (1.3) 14.8 (1.8) 22.9 (0.8)*** 19.2 (1.2) 22.9 (1.3)* 26.7 (0.4) 27.1 (1)
FAB 11 (1.3) 10 (0.7) 9.9 (1) 13.1 (0.7)* 14.6 (2) 9.7 (1.8) 11 (1.9) 10 (0.9) 9.9 (0.8) 10.4 (0.8) 6.1 (1.4) 11.7 (0.6)*** 11.9 (0.8) 11.3 (0.8) 15.1 (0.3) 15 (0.9)
FCSRT free recall
(/48)
20.5 (3.2) 20.3 (3.5) 16.8 (3) 14.3 (2.5) 23.7 (5.9) 22.2 (5.1) 19.6 (1.9) 15.7 (3.3) 19.5 (2.5) 19.8 (2.5) 17.9 (1.5) 19.3 (5.5) 17.6 (1.9) 12.5 (2) 24.6 (0.8) 26.9 (2.2)
FCSRT total
recall (/48)








9.3 (1.3) 8.7 (1.3) 8.8 (1.2) 4.3 (1.1) 9.3 (3) 8.5 (2.6) 7.1 (1) 8.3 (1.6) 5.7 (1.2) 7.8 (1.2) 6.3 (0.7) 8.3 (2.4) 1.8 (0.8) 6.2 (0.8)*** 8.8 (0.4) 10.8 (0.2)
Abbreviations: Ab, amyloid b; AD, Alzheimer’s disease; CBS, corticobasal syndrome; CSF, cerebrospinal fluid; depr, depression; FAB, Frontal Assessment Battery; FCSRT, Free and Cued Selective Reminding
Test; FTD, frontotemporal dementia; free delayed re, free delayed recall; LBD, Lewy body disease; lv-PPA, logopenic primary progressive aphasia; MMSE, Mini-Mental State Examination; nfv-PPA, nonfluent/
agrammatic primary progressive aphasia; PCA, posterior cortical atrophy; PSP, progressive supranuclear palsy; p-tau, phosphorylated tau; react to cueing, reactivity to cueing; SCD, subjective cognitive decline;
sv-PPA, semantic primary progressive aphasia; total delayed re, total delayed recall.
NOTE. FCSRT subtests that did not yield any significant differences between biomarker (1) and biomarker (2) subgroups for a given patient group are not indicated in the table. In brackets: standard deviations.
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sensitivity of 83% and a specificity of 72% to diagnose
typical AD versus all the other patient groups of the study.
However, an amnesic syndrome of the hippocampal type
was also present in 105 of 385 (27.3%) of patients with a
diagnosis other than AD including 79 of 314 (25.2%) of pa-
tients with other neurodegenerative diseases and 26 of 71
(36.6%) of patients with depression. More specifically,
FCSRT scores indicative of an amnesic syndrome of the hip-
pocampal type were found in patients with LBD (40.9%),
PSP (37.5%), bv-FTD (31.9%), nfv-PPA (27.3%), PCA
(22.7%), sv-PPA (22%), CBS (22%), and lv-PPA (5.8%).
However, normal FCSRT scores had a relatively acceptable
specificity to screen out these diseases in populations that
would be designated to detect typical AD (LBD [59.1%],
PSP [62.5%], bv-FTD [68.1%], nfv-PPA [72.7%], PCA
[77.3%], sv-PPA [78.1%], CBS [78.0%], and lv-PPA
[94.2%]).
In these neurodegenerative diseases, the biomarker sta-
tus did not influence the presence or absence of an amnesic
syndrome of the hippocampal type, except for the LBD
group who had poorer FCSRT scores when AD biomarkers
were positive. Conversely, biomarker-positive patients,
compared with biomarker-negative subjects, performed
worse on the MMSE and/or the FAB. Results are summa-
rized in Table 2. Regarding correlation analyses, they
showed that higher biomarker ratios (p-tau181/Ab1–42)
indicative of underlying AD pathology were related to
poorer free recall and total recall scores and to more intru-
sions on the FCSRT (all Ps , .001) when considering the
whole group of degenerative diseases (AD plus the eight
other degenerative conditions). However, no significant
correlations (all Ps . .1) were found for the AD group
alone or for the entire group of the eight other degenerative
conditions.4. Discussion
The present study is, to our knowledge, the first to
assess the reliability of the FCSRT for detecting typical
AD in a large-scale monocenter cohort applying the clin-
ical phenotype AD diagnostic categorization recommended
by the advanced IWG-2 criteria [3] and applying strin-
gently the most recent diagnostic criteria for eight other
clinically relevant age-related neurodegenerative diseases.
All previous studies using this memory test were conducted
in research settings to distinguish merely prodromal AD
from stable MCI or SCD [31] or in small-cohort investiga-
tions with highly selected patient groups without any
biomarker information [5,6]. The only exception is the
investigation of Wagner et al. [32] using CSF biomarkers
in 185 MCI subjects, yet without including other identified
neurodegenerative diseases. Addressing these limitations,
our study provides a robust validation of the reliability of
the FCSRT to identify typical AD among populations of
patients with various neurodegenerative diseases.Compared with studies on MCI or SCD, in which the
free recall and total recall were the most useful scores to
distinguish typical AD from stable MCI or SCD [4,9,31],
our findings show that all subscores of the test are
sensitive to typical AD whatever its stage, but that the
“delayed total recall” and the “number of intrusions” are
the most discriminative indicators. These results are in
line with the previous studies suggesting that intrusions
depend critically on the hypometabolism of hippocampal
regions, but that prefrontal regions, also damaged in
more advanced AD, might play an additional role [33].
They also reinforce and validate the diagnostic value of
the FCSRT in clinical practice. Furthermore, the fact that
there is no difference in the magnitude of the impairment
in its subscores between AD dementia and prodromal AD
provides evidence for its usefulness in assessing and de-
tecting predementia stages of AD. Such stages correspond
to an earlier phase of the disease process and, therefore, to
an optimal therapeutic time window.
Low scores of free recall and total recall were also
found in various other neurodegenerative diseases and
in depression. In neurodegenerative diseases such
abnormal scores are probably related to severe cognitive
changes, including language or profound executive
dysfunction, which might interfere with the performance
on the FCSRT and be wrongly interpreted as episodic
amnesia of the hippocampal type. However, abnormal
FCSRT scores might also result from genuine damage
to the hippocampi, which has been evidenced in several
neurodegenerative diseases such as bv-FTD, LBD, PSP,
and sv-PPA [34–37]. The concept of the amnesic
syndrome of the hippocampal type should, therefore, be
used cautiously suggesting that abnormal FCSRT scores
do not have an absolute specificity for typical AD
diagnosis. The sensitivity of 100% not only makes the
FCSRT an excellent test for detecting typical AD
patients but also provides some false positive results
(specificity 75%) concerning other neurodegenerative
diseases. This limited specificity for typical AD is a
limitation of the test indicating the necessity to take
into account the IWG criteria positing that typical AD
is a clinicobiological entity [2,3], the identification of
which depends on both a noninvasive clinical criterion
(abnormal FCSRT scores) and a biological criterion
such as positive AD CSF biomarkers or amyloid-
detecting PET. One should, however, be aware that our
study also shows that there are several non-AD degener-
ative diseases that have positive CSF biomarkers. This
latter finding represents a challenge for the development
of new memory tests with a similar sensitivity as the
FCSRT but still better specificity for typical AD. It should
also be noted that the exclusive application of biological
markers is not sufficient because they do not provide the
syndromic information that clinically defines a given dis-
ease such as typical amnesic AD. Thus, memory tests
such as the FCSRT remain indispensable, non-invasive,
M. Teichmann et al. / Alzheimer’s & Dementia - (2017) 1-11 9inexpensive, and easy-to-obtain first-line tools that screen
for candidates for therapeutic trials in typical AD and that
provide important end points evaluating potential trial ef-
ficiency.
Despite no absolute specificity of the FCSRT for typical
amnesic AD, we advocate for continuing to use the term
“amnesic syndrome of the hippocampal type” as reflected
by FCSRT scores bearing in mind that it is mostly evoca-
tive of typical AD when (1) it is central or even isolated
(criteria for other neurodegenerative conditions unfulfilled,
for example, no socio-emotional changes suggestive of bv-
FTD, no extrapyramidal symptoms as in LBD, CBS, PSP);
(2) it is most severe; and (3) when it is associated
with other signs of hippocampal dysfunction such as
intrusions [38].
Our study also confirms, enriches, and opens up the
atypical AD spectrum proposed by the IWG [3] that
included PCA, lv-PPA, and the so-called “frontal variant”
suggestive of bv-FTD. In line with this view, PCA and
lv-PPA are in our investigation among the clinical pheno-
types that are most frequently associated with positive
AD biomarkers (80%). On the other hand, the prevalence
of the frontal variant of AD is among the rarest of all syn-
dromes with an AD biomarker profile in our study
(14.5%). Our findings also highlight that several other
neurodegenerative entities can be associated with an AD
biomarker profile: LBD, which could be considered as
mixed AD/LBD pathology as shown by neuropathological
data [39], but also CBS that was the fourth most prevalent
phenotype associated with an AD biomarker profile. Simi-
larly, nfv-PPA and sv-PPA can be associated with Alz-
heimer’s pathology and thus, in some cases, constitute
atypical variants of AD. Interestingly, positive CSF AD
biomarkers in these diseases are not related to lower
FCSRT scores and numerical CSF biomarker ratios do
not correlate with lower FCSRT scores in these diseases
or in the typical AD group. These latter results can be ex-
plained by the fact that, in contrast with memory tests, the
longitudinal changes in CSF biomarkers are not correlated
with disease progression [40]. They also suggest that the
brain lesion load of p-tau and Ab might not be a reliable
predictor of memory deficits in neurodegenerative dis-
eases.
In summary, based on the paradigm of the IWG
considering that AD is a clinicobiological entity using
in vivo biomarkers [2,3], our data open-up the spectrum
of atypical AD variants including biomarker-positive
forms of PCA, the three main PPA variants, CBS, and
bv-FTD. Depending on the syndrome, underlying AD pa-
thology can be considered either a co-occurring pathol-
ogy (e.g., for LBD) or as the main pathology. The fact
that in our cohort, the prevalence of an AD-positive
biomarker profile in other neurodegenerative diseases
matches the prevalence described in clinicopathological
cohorts [21,41] suggests that the rate of false positive
is low. This outcome is probably linked to the fact thatthe combined p-tau181/Ab1–42 cut-off chosen to consider
a positive AD biomarker profile is stringently derived
from clinicopathological and large clinical cohorts [27–
29]. The clinical differential diagnostic value of the
AD CSF biomarker profile has been recently
demonstrated in a large-scale multicenter memory
clinic–based cohort study [42]. The single CSF
biomarker Ab1–42 value showed the best diagnostic accu-
racy among the CSF biomarkers but the combined
p-tau181/Ab1–42 model improved numerically the speci-
ficity for the discrimination between AD dementia and
SCD or depression.
It should be noted that monocentric studies might war-
rant biases, related to the great homogeneity of neuropsy-
chological and biological assessments that would not
allow for a generalization to more heterogeneous routine
assessments in national or international patient populations.
Thus, homogenization of standardized cognitive testing
and procedures of biomarker analyses represent an impor-
tant challenge for the international community. One should
also note that the mean age at symptom onset of the partic-
ipants of this investigation (64.1 6 9.3 years) is also lower
than the mean age of AD patients diagnosed in France [43],
which reflects our center’s referral nature for young onset
AD and rare dementias. This discrepancy, however, appears
to be a methodological advantage because at younger ages,
the symptoms are likely to be disease specific and not the
manifestation of comorbidity or mixed pathologies that
hinder the discriminative power of cognitive tests such as
the FCSRT.
In conclusion, the FCSRT, which was already recom-
mended for AD enrichment during the inclusion in clin-
ical trials on SCD or MCI populations and which was
thought to be useful to distinguish typical AD from other
neurodegenerative conditions, has now demonstrated its
value and discriminative reliability at the cohort level.
The FCSRT should also be implemented in memory cen-
ter’s clinical routine keeping in mind that its specificity
for typical AD is not absolute. However, decreased per-
formance notably in delayed total recall of the FCSRT
and intrusions were found to be particularly indicative
of typical AD. Finally, our study emphasizes the exis-
tence of multiple “atypical AD” variants, among which
PCA and logopenic primary progressive aphasia are the
most prevalent, followed by CBS, nfv-PPA, sv-PPA, and
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1. Systematic review: We performed an exhaustive re-
view of peer-reviewed articles (PubMed and MED-
LINE) revealing not any investigation of the
specificity for typical Alzheimer’s disease (AD) of
the Free and Cued Selective Reminding Test
(FCSRT), recommended by the International Work-
ing Group.
2. Interpretation: Our clinical-cerebrospinal fluid (CSF)
biomarker investigation of a large cohort of typical
AD and eight other neurodegenerative diseases,
subjective cognitive decline, and depression showed
(1) the FCSRT sensitively detects typical AD in large
patient settings with neurodegenerative diseases, (2)
the FCRST has no absolute specificity at the indi-
vidual level, (3) the spectrum of atypical AD should
be opened up to multiple biomarker-positive degen-
erative diseases including, according to decreasing
prevalence, posterior cortical atrophy, logopenic
primary progressive aphasia, corticobasal syndrome,
nonfluent/agrammatic primary progressive aphasia,
semantic primary progressive aphasia, and fronto-
temporal dementia of the behavioral type.
3. Future directions: FCSRT reliability at the group
level will be important for pharmacological trials
by minimizing false non-AD inclusions. Widening
the concept of atypical AD requires investigations of
neuropathologic series to assess the proportions of
AD in neurodegenerative diseases.
References
[1] Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease.
Nat Rev Neurol 2011;7:137–52.
[2] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P,
Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s
disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;
6:734–46.
[3] Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL,
Blennow K, et al. Advancing research diagnostic criteria for Alz-
heimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–29.
[4] Auriacombe S, Helmer C, Amieva H, Berr C, Dubois B, Dartigues JF.
Validity of the free and cued selective reminding test in predicting de-
mentia: the 3C study. Neurology 2010;74:1760–7.
[5] Epelbaum S, Benisty S, Reyes S, O’Sullivan M, Jouvent E, D€uring M,
et al. Verbal memory impairment in subcortical ischemic vascular dis-
ease: a descriptive analysis in CADASIL. Neurobiol Aging 2011;
32:2172–82.
[6] Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for de-
mentia by memory testing. Neurology 1988;38:900–3.
[7] Pasquier F, Grymonprez L, Lebert F, Van der Linden M. Memory
impairment differs in frontotemporal dementia and Alzheimer’s dis-
ease. Neurocase 2001;7:161–71.[8] Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alz-
heimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 1993;
50:374–9.
[9] Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S,
et al. Amnestic syndrome of the medial temporal type identifies pro-
dromal AD: a longitudinal study. Neurology 2007;69:1859–67.
[10] Tounsi H, Deweer B, Ergis AM, Van der Linden M, Pillon B,
Michon A, et al. Sensitivity to semantic cuing: an index of episodic
memory dysfunction in early Alzheimer disease. Alzheimer Dis Assoc
Disord 1999;13:38–46.
[11] Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer’s dis-
ease? Lancet Neurol 2004;3:246–8.
[12] Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M,
Chetelat G, et al. A conceptual framework for research on subjective
cognitive decline in preclinical Alzheimer’s disease. Alzheimers De-
ment 2014;10:844–52.
[13] Autorite de Sante H. Maladie d’Alzheimer: diagnostic et prise en
charge. Saint-Denis La Plaine, France: Haute Autorite de Sante; 2011.
[14] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A prac-
tical method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975;12:189–98.
[15] Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal
Assessment Battery at bedside. Neurology 2000;55:1621–6.
[16] Van der Linden M, Coyette F, Poitrenaud J, Kalafat M, Calicis F,
Wyns C, et al. L’epreuve de rappel libre/rappel indice a 16 items
(RL/RI-16). In: Solal, ed. L’evaluation des troubles de la memoire:
presentation de quatre tests de memoire episodique avec leur
etalonnage. France, Solal: Marseille; 2004. p. 25–47.
[17] Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behav-
ioural variant of frontotemporal dementia. Brain 2011;134:2456–77.
[18] Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M,
Cappa SF, et al. Classification of primary progressive aphasia and its
variants. Neurology 2011;76:1006–14.
[19] Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B,
et al. Criteria for the diagnosis of corticobasal degeneration.
Neurology 2013;80:496–503.
[20] Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al.
Clinical research criteria for the diagnosis of progressive supranuclear
palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-
SPSP international workshop. Neurology 1996;47:1–9.
[21] Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE,
Crook R, et al. Clinical, genetic, and neuropathologic characteristics
of posterior cortical atrophy. Neurology 2004;63:1168–74.
[22] McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H,
et al. Diagnosis and management of dementia with Lewy bodies: third
report of the DLB Consortium. Neurology 2005;65:1863–72.
[23] American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders, 5th Edition. Washington, DV: American Psychi-
atric Association; 2013.
[24] Montgomery SA, Asberg M. A new depression scale designed to be
sensitive to change. Br J Psychiatry 1979;134:382–9.
[25] Fazekas F, Schmidt R, Kleinert R, Kapeller P, Roob G, Flooh E. The
spectrum of age-associated brain abnormalities: their measurement
and histopathological correlates. J Neural Transm Suppl 1998;
53:31–9.
[26] Caroppo P, Le Ber I, Camuzat A, Clot F, Naccache L, Lamari F, et al.
Extensive white matter involvement in patients with frontotemporal
lobar degeneration: think progranulin. JAMANeurol 2014;71:1562–6.
[27] Seeburger JL,HolderDJ,CombrinckM, JoachimC,LaterzaO,TanenM,
et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed
Alzheimer’s disease fromother dementias andhealthycontrols in theOP-
TIMA cohort. J Alzheimers Dis 2015;44:525–39.
[28] Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P,
Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau pro-
teins as biomarkers of Alzheimer-type pathologic changes in the brain.
Arch Neurol 2009;66:382–9.
M. Teichmann et al. / Alzheimer’s & Dementia - (2017) 1-11 11[29] Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N,
Zetterberg H, et al. The cerebrospinal fluid “Alzheimer profile”: easily
said, but what does it mean? Alzheimers Dement 2014;10:713–23.
[30] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s dis-
ease: recommendations from the National Institute on Aging-Alz-
heimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement 2011;7:263–9.
[31] Di Stefano F, Epelbaum S, Coley N, Cantet C, Ousset PJ, Hampel H,
et al. Prediction of Alzheimer’s disease dementia: data from the Gui-
dAge Prevention Trial. J Alzheimers Dis 2015;48:793–804.
[32] Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F,
et al. Biomarker validation of a cued recall memory deficit in prodro-
mal Alzheimer disease. Neurology 2012;78:379–86.
[33] Desgranges B, Baron JC, Giffard B, Chetelat G, Lalevee C, Viader F,
et al. The neural basis of intrusions in free recall and cued recall: a PET
study in Alzheimer’s disease. Neuroimage 2002;17:1658–64.
[34] Cordato NJ, Halliday GM, Harding AJ, HelyMA,Morris JG. Regional
brain atrophy in progressive supranuclear palsy and Lewy body dis-
ease. Ann Neurol 2000;47:718–28.
[35] Padovani A, Borroni B, Brambati SM, Agosti C, Broli M, Alonso R,
et al. Diffusion tensor imaging and voxel based morphometry study
in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry
2006;77:457–63.
[36] Hornberger M, Wong S, Tan R, Irish M, Piguet O, Kril J, et al. In vivo
and post-mortem memory circuit integrity in frontotemporal dementia
and Alzheimer’s disease. Brain 2012;135:3015–25.[37] Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM,
Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three var-
iants of primary progressive aphasia. Ann Neurol 2004;55:335–46.
[38] Lee GP, Loring DW, Flanigin HF, Smith JR, Meador KJ. Electrical
stimulation of the human hippocampus produces verbal intrusions dur-
ing memory testing. Neuropsychologia 1988;26:623–7.
[39] Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De
Leenheir E, et al. Amyloid pathology influences abeta1-42 cerebrospi-
nal fluid levels in dementia with Lewy bodies. J Alzheimers Dis 2013;
35:137–46.
[40] Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ,
Kok A, Rijmen F, et al. Longitudinal changes of CSF biomarkers in
memory clinic patients. Neurology 2007;69:1006–11.
[41] Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C,
Bigio EH. Asymmetry and heterogeneity of Alzheimer’s and fronto-
temporal pathology in primary progressive aphasia. Brain 2014;
137:1176–92.
[42] Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J,
et al. CSF biomarkers for the differential diagnosis of Alzheimer’s dis-
ease: a large-scale international multicenter study. Alzheimers Dement
2015;11:1306–15.
[43] Pradier C, Sakarovitch C, Le Duff F, Layese R, Metelkina A,
Anthony S, et al. The mini mental state examination at the time of
Alzheimer’s disease and related disorders diagnosis, according to
age, education, gender and place of residence: a cross-sectional study
among the French National Alzheimer database. PLoS One 2014;
9:e103630.
